Physician profile
Michael Cohen
NPI 1770658601
$1,230.62
in general payments reported to CMS, 2019-2025
23 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $12.04 · 2021: $222 · 2022: $277 · 2023: $157 · 2024: $194 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $289.75 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $156.59 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $70.40 | 2019-2024 | |
| Sanofi Pasteur INC. | $60.63 | 2019-2022 | |
| Neos Therapeutics, LP | $56.65 | 2020-2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Kaleo, INC. | $52.97 | 2019-2024 | Auvi-Q |
| Hologic Sales and Service, LLC | $50.02 | 2019-2025 | Third Wave, Aptima |
| Seqirus USA INC | $49.68 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
| Novartis Pharmaceuticals Corporation | $47.21 | 2019 | |
| Merck Sharp & Dohme LLC | $45.80 | 2022-2025 | Vaxneuvance, Rotateq, Gardasil 9 |
| Sobi, INC | $43.46 | 2021-2023 | |
| Tris Pharma INC | $42.19 | 2022-2024 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $37.41 | 2024 | |
| Genentech USA, INC. | $34.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.57 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $32.52 | 2021 | |
| Neurelis, INC. | $31.91 | 2021 | |
| Alk-Abello, INC | $27.04 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $16.84 | 2023 | Voxzogo 1.2mg |
| Shire North American Group INC | $14.91 | 2019 | |
| Philips North America LLC | $14.83 | 2023 | |
| Vertical Pharmaceuticals, LLC | $11.47 | 2019 | |
| Glaxosmithkline, LLC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.